Update information

Update information

March 2017: We updated recommendations in section 1.7 on chemoprevention for women with no personal history of breast cancer. These recommendations are marked as [2017].

June 2013: We updated and included new recommendations on genetic testing thresholds, surveillance and risk reduction and treatment strategies for people without breast cancer who are at increased risk because of a family history of breast, ovarian or a related cancer. We included new recommendations on genetic testing thresholds, subsequent surveillance and risk reduction and treatment strategies for people with a diagnosis of breast cancer and a family history of breast, ovarian or a related cancer. These recommendations are marked as [2013].

July 2006: We updated recommendations in section 1.6 on surveillance and strategies for early detection of breast cancer. These recommendations are marked as [2006].

Minor changes since publication

May 2021: We removed the note about the off-label use of tamoxifen because this is now licensed for preventing breast cancer.

November 2019: A link to patient decision aids was added. Recommendation 1.6.5 was updated to add a cross-reference to recommendation 1.6.18 to clarify the topics that should be discussed with a person before making a mammographic surveillance decision.

ISBN: 978-1-4731-0160-9

  • National Institute for Health and Care Excellence (NICE)